{
    "Clinical Trial ID": "NCT00063570",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Bi-Weekly Schedule",
        "  Pemetrexed: 500 mg/m2, intravenous (IV), every 14 days, until disease progression.",
        "  Gemcitabine: 1500 mg/m2, intravenous (IV), every 14 days, until disease progression.",
        "INTERVENTION 2: ",
        "  21-Day Schedule",
        "  Pemetrexed: 500 mg/m2, intravenous (IV), every 21 days, until disease progression.",
        "  Gemcitabine: 1000 mg/m2, intravenous (IV) on Days 1 and 8 of a 21-day cycle, until disease progression."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel).",
        "  Less than 3 different chemotherapy treatments for metastatic disease.",
        "  Prior treatment with hormonal and/or radiation therapy.",
        "  Must have disease that can be measured.",
        "  Must be able to take care of self needs for example personal hygiene",
        "Exclusion Criteria:",
        "  Must not be pregnant or breast-feeding.",
        "  Cancer that has spread to the brain.",
        "  Treatment with Gemcitabine or Pemetrexed",
        "  Unable to take folic acid or Vitamin B12",
        "  Treatment for another cancer within the last 5 years"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Overall Tumor Response",
        "  Best overall (confirmed) response recorded from start of treatment until disease progression/recurrence, start of other anti-tumor therapy/intervention, or end of trial, whichever comes first. Response must be confirmed at least 6 weeks from previous scans. Best overall response assignment depends on both measurement and confirmation criteria.",
        "  Time frame: Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated",
        "Results 1: ",
        "  Arm/Group Title: Bi-Weekly Schedule",
        "  Arm/Group Description: Pemetrexed: 500 mg/m2, intravenous (IV), every 14 days, until disease progression.",
        "  Gemcitabine: 1500 mg/m2, intravenous (IV), every 14 days, until disease progression.",
        "  Overall Number of Participants Analyzed: 52",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response: 2",
        "  Partial Response: 8",
        "  Stable Disease: 26",
        "  Progressive Disease: 14",
        "Unknown: 2",
        "Results 2: ",
        "  Arm/Group Title: 21-Day Schedule",
        "  Arm/Group Description: Pemetrexed: 500 mg/m2, intravenous (IV), every 21 days, until disease progression.",
        "  Gemcitabine: 1000 mg/m2, intravenous (IV) on Days 1 and 8 of a 21-day cycle, until disease progression.",
        "  Overall Number of Participants Analyzed: 21",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response: 0",
        "  Partial Response: 5",
        "  Stable Disease: 10",
        "  Progressive Disease: 6",
        "Unknown: 0"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 17",
        "  Anaemia 2/52 (3.85%)",
        "  Febrile neutropenia 4/52 (7.69%)",
        "  Pancytopenia 1/52 (1.92%)",
        "  Thrombocytopenia 0/52 (0.00%)",
        "  Abdominal pain 1/52 (1.92%)",
        "  Constipation 1/52 (1.92%)",
        "  Pyrexia 2/52 (3.85%)",
        "  Hepatic failure 1/52 (1.92%)",
        "  Hyperbilirubinaemia 1/52 (1.92%)",
        "  Device related infection 1/52 (1.92%)",
        "  Pneumonia 2/52 (3.85%)",
        "  Sepsis 1/52 (1.92%)",
        "Adverse Events 2:",
        "  Total: 7",
        "  Anaemia 0/21 (0.00%)",
        "  Febrile neutropenia 1/21 (4.76%)",
        "  Pancytopenia 0/21 (0.00%)",
        "  Thrombocytopenia 1/21 (4.76%)",
        "  Abdominal pain 0/21 (0.00%)",
        "  Constipation 0/21 (0.00%)",
        "  Pyrexia 1/21 (4.76%)",
        "  Hepatic failure 0/21 (0.00%)",
        "  Hyperbilirubinaemia 0/21 (0.00%)",
        "  Device related infection 0/21 (0.00%)",
        "  Pneumonia 0/21 (0.00%)",
        "  Sepsis 0/21 (0.00%)"
    ]
}